Chapter

Economic evaluations of newborn screening

Scott D. Grosse

in Economic Evaluation in Child Health

Published in print October 2009 | ISBN: 9780199547494
Published online February 2010 | e-ISBN: 9780191720055 | DOI: http://dx.doi.org/10.1093/acprof:oso/9780199547494.003.06
 Economic evaluations of newborn screening

More Like This

Show all results sharing this subject:

  • Public Health and Epidemiology

GO

Show Summary Details

Preview

Screening for metabolic, endocrine, and other diseases in newborns is performed through the laboratory analysis of dried blood spot specimens. This chapter reviews economic evaluations of newborn dried blood spot screening strategies published during 2002-07, focusing on the cost-effectiveness of screening for cystic fibrosis, congenital adrenal hyperplasia, and medium chain acyl-CoA dehydrogenase deficiency (MCADD). The use of tandem mass spectrometry (MS/MS) to detect MCADD is presented in detail, through examinations of the costs of screening and medical management, and of outcomes, including quality-adjusted life year (QALY) measurement, disability, and mortality. Ways to generate higher quality evidence are presented. The chapter concludes with a discussion of the use of economic evaluations to inform newborn screening policies.

Keywords: newborn screening; metabolic disorders; tandem mass spectrometry; cost-effectiveness; QALY; health policy

Chapter.  8947 words. 

Subjects: Public Health and Epidemiology

Full text: subscription required

How to subscribe Recommend to my Librarian

Buy this work at Oxford University Press »

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.